Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Experts are questioning whether the groups’ financial ties could push them to put drugmakers’ interests ahead of the people they represent...
Advocating for yourself is the best medicine.
A cancer diagnosis often means extreme financial stress—and fights with insurance providers.
Stop me if you’ve heard this one before.
Branded drugs with expired patents but without generic competition may keep prices high and ultimately hurt patients.
While this program is intended for brand and generic drugs, we know it will support more efficient development and production of generics.
A look at the 2019 State of the Union address
Older drugs, many on the market for years, are rising in cost much faster than inflation.
These drugs, made from living organisms, are big moneymakers partly because they have little competition. It’s a different story in Europe.
“The result of this progress is that we openly talk about curing cancers that were recently fatal,” says Commissioner Gottlieb.
A recent study found that 42% of patients depleted 100 percent of their assets—an average loss of $92,000—within two years of diagnosis.
A new study examines the clinical and economic impact of new direct-acting antivirals.
Plans will be able to add restrictions on certain drugs to treat diseases like cancer, requiring patients to first try cheaper drugs.
Peter J. Pitts is president of the Center for Medicine in the Public Interest.
The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.
Nonprescription drugs are used by consumers without the supervision of a health care professional and require a very high safety margin.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.